文献速递泌尿男性生殖肿瘤

PET/CT评估雄激素受体表达与糖酵解活性作为转移性去势抵抗性前列腺癌的预后生物标志物

Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer.
PubMed 文献 · JAMA Oncol · 2018-01-01

该研究在133例未接受ARSi治疗的mCRPC患者中,使用[18F]-FDHT和[18F]-FDG PET/CT评估雄激素受体表达和糖酵解活性,发现影像表型异质性对生存有独立负面影响,尤其是AR0Glyc1病灶预后最差。49%患者至少有一个AR0Glyc1病灶,可能提示ARSi耐药。

要点

  • PET/CT影像表型异质性在病灶和患者层面均有临床意义
  • AR0Glyc1病灶对生存的负面影响最大(HR 1.11)
  • 49%患者至少有一个AR0Glyc1病灶,可能提示ARSi耐药

核心结论

  • PET/CT影像表型异质性在病灶和患者层面具有临床相关性,多数mCRPC病灶表达AR,与ARSi初始获益一致。

主要发现

  • 2405个PET/CT阳性病灶(中位每患者12.0个)中,1713个(71.2%)为AR1Glyc1,386个(16.0%)为AR1Glyc0,306个(12.7%)为AR0Glyc1。
  • 多因素分析显示各表型对生存均有独立负面影响,AR0Glyc1病灶最显著(HR 1.11,95%CI 1.05-1.16,P<.001),其次为AR1Glyc1(HR 1.05,95%CI 1.03-1.06,P<.001)和AR1Glyc0(HR 1.03,95%CI 1.00-1.05,P=.048)。
  • 患者特异性分组:一致型34例(25.6%),AR主导型33例(24.8%),Glyc主导型40例(30.1%),混合型26例(19.5%)。
  • 49%患者(第3和第4组)至少有一个AR0Glyc1病灶,该表型对生存负面影响最大,可能由于ARSi耐药。

临床怎么用

  • PET/CT影像表型异质性可用于区分可能从ARSi获益的患者与需要替代治疗的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Androgen receptor-signaling inhibitor (ARSi) drugs prolong life in metastatic castration-resistant prostate cancer (mCRPC), but such tumors eventually become resistant and progress. Comprehensive positron emission tomography/computed tomography (PET/CT) imaging using fluoro-2-D-deoxyglucose F 18 ([18F]-FDG) for glycolysis (Glyc) and fluorodihydrotestosterone F 18 ([18F]-FDHT) for androgen receptor (AR) expression determine heterogeneity of imaging phenotypes, which may be useful in distinguishing patients who will benefit from ARSi drugs from those who need alternative treatments. OBJECTIVE: To test the hypothesis that PET/CT-based assessments of AR expression and glycolytic activity would reveal heterogeneity affecting prognosis. DESIGN, SETTING, AND PARTICIPANTS: Between April 6, 2007, and October 4, 2012, patients with mCRPC underwent imaging with both [18F]-FDG and [18F]-FDHT at Memorial Sloan Kettering Cancer Center. The patients were naive to ARSi treatment with enzalutamide or abiraterone acetate and were referred during documented disease progression. Image-directed biopsy determined the presence or absence of prostate cancer at positive imaging sites. INTERVENTIONS: PET/CT imaging was performed with [18F]-FDHT and [18F]-FDG; select individual lesions were biopsied to correlate imaging phenotype with histologic findings. MAIN OUTCOMES AND MEASURES: All metabolically active lesions were interpreted as [18F]-FDHT-positive (AR1) or [18F]-FDHT-negative (AR0) and as [18F]-FDG-positive (Glyc1) or [18F]-FDG-negative (Glyc0). Correlation was performed with overall survival for both individual lesion imaging phenotype as well as patient-specific imaging phenotype. RESULTS: The mean (SD) age of the 133 patients was 68 (8.6) years. Imaging phenotypes of 2405 PET/CT-positive lesions (median, 12.0 per patient) included 1713 (71.2%) AR1Glyc1, 386 (16.0%) AR1Glyc0, and 306 (12.7%) AR0Glyc1. On multivariate analysis, each phenotype had an independent negative impact effect on survival, most pronounced for AR0Glyc1 lesions (hazard ratio [HR], 1.11; 95% CI, 1.05-1.16; P < .001), followed by AR1Glyc1 lesions (HR, 1.05; 95% CI, 1.03-1.06; P < .001) and AR1Glyc0 lesions (HR, 1.03; 95% CI, 1.00-1.05; P = .048). When sorted by lesion type, 4 patient-specific groups emerged: (1) concordant, with all AR1Glyc1 (34 patients [25.6%]); (2) AR predominant, with AR1Glyc1 and varying numbers of AR1Glyc0 (33 [24.8%]); (3) Glyc predominant, with AR1Glyc1 and varying numbers of AR0Glyc1 (40 [30.1%]); and (4) mixed, with AR1Glyc1 plus a mixture of varying numbers of AR1Glyc0 and AR0Glyc1 (26 [19.5%]). CONCLUSIONS AND RELEVANCE: Heterogeneity of PET/CT imaging phenotype has clinical relevance on a lesion and individual patient level. With regard to mCRPC lesions, most express ARs, consistent with initial benefit of ARSi drugs. On a patient basis, 49% (groups 3 and 4) had at least 1 AR0Glyc1 lesion-the imaging phenotype with the most negative effect on survival, possibly due to ARSi resistance.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Fox JJ, Gavane SC, Blanc-Autran E, et al. Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. JAMA Oncol. 2018. PMID: 29121144. doi:10.1001/jamaoncol.2017.3588

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。